CA2599327A1 - Human autism susceptibility genes encoding a neurotransmitter transporter and uses thereof - Google Patents
Human autism susceptibility genes encoding a neurotransmitter transporter and uses thereof Download PDFInfo
- Publication number
- CA2599327A1 CA2599327A1 CA002599327A CA2599327A CA2599327A1 CA 2599327 A1 CA2599327 A1 CA 2599327A1 CA 002599327 A CA002599327 A CA 002599327A CA 2599327 A CA2599327 A CA 2599327A CA 2599327 A1 CA2599327 A1 CA 2599327A1
- Authority
- CA
- Canada
- Prior art keywords
- autism
- slc6a1
- slc6a11
- gene
- disorder
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 208000020706 Autistic disease Diseases 0.000 title claims abstract description 236
- 206010003805 Autism Diseases 0.000 title claims abstract description 231
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 65
- 102000005665 Neurotransmitter Transport Proteins Human genes 0.000 title description 6
- 108010084810 Neurotransmitter Transport Proteins Proteins 0.000 title description 6
- 102000005028 SLC6A1 Human genes 0.000 claims abstract description 227
- 101150064359 SLC6A1 gene Proteins 0.000 claims abstract description 115
- 101150111297 SLC6A11 gene Proteins 0.000 claims abstract description 108
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 95
- 208000029560 autism spectrum disease Diseases 0.000 claims abstract description 80
- 230000035772 mutation Effects 0.000 claims abstract description 61
- 238000011282 treatment Methods 0.000 claims abstract description 39
- 230000014509 gene expression Effects 0.000 claims abstract description 29
- 108060007759 SLC6A1 Proteins 0.000 claims description 135
- 238000000034 method Methods 0.000 claims description 134
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 111
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 110
- 229920001184 polypeptide Polymers 0.000 claims description 107
- 230000004075 alteration Effects 0.000 claims description 98
- 239000012634 fragment Substances 0.000 claims description 65
- 150000001875 compounds Chemical class 0.000 claims description 44
- 230000000694 effects Effects 0.000 claims description 37
- 238000012360 testing method Methods 0.000 claims description 29
- 230000003321 amplification Effects 0.000 claims description 19
- 238000003199 nucleic acid amplification method Methods 0.000 claims description 19
- 238000009396 hybridization Methods 0.000 claims description 16
- 230000004044 response Effects 0.000 claims description 14
- 238000012163 sequencing technique Methods 0.000 claims description 12
- 102000054766 genetic haplotypes Human genes 0.000 claims description 10
- 230000002411 adverse Effects 0.000 claims description 8
- 238000004519 manufacturing process Methods 0.000 claims description 7
- 239000000556 agonist Substances 0.000 claims description 5
- 108091030071 RNAI Proteins 0.000 claims description 4
- 108700008625 Reporter Genes Proteins 0.000 claims description 4
- 230000004913 activation Effects 0.000 claims description 4
- 230000000692 anti-sense effect Effects 0.000 claims description 4
- 230000009368 gene silencing by RNA Effects 0.000 claims description 4
- 230000005764 inhibitory process Effects 0.000 claims description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims description 4
- 238000011321 prophylaxis Methods 0.000 claims description 4
- 239000005557 antagonist Substances 0.000 claims description 3
- 102000005020 SLC6A11 Human genes 0.000 claims 11
- 108060007750 SLC6A11 Proteins 0.000 claims 11
- 239000003814 drug Substances 0.000 abstract description 26
- 229940079593 drug Drugs 0.000 abstract description 23
- 210000000349 chromosome Anatomy 0.000 abstract description 18
- 108700028369 Alleles Proteins 0.000 abstract description 17
- 238000003745 diagnosis Methods 0.000 abstract description 17
- 238000012216 screening Methods 0.000 abstract description 16
- 238000001514 detection method Methods 0.000 abstract description 11
- 208000012202 Pervasive developmental disease Diseases 0.000 abstract description 10
- 208000036640 Asperger disease Diseases 0.000 abstract description 8
- 201000006062 Asperger syndrome Diseases 0.000 abstract description 8
- 230000002265 prevention Effects 0.000 abstract description 7
- 230000001225 therapeutic effect Effects 0.000 abstract description 6
- 208000019901 Anxiety disease Diseases 0.000 abstract description 5
- 208000024825 childhood disintegrative disease Diseases 0.000 abstract description 5
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 abstract description 4
- 230000036506 anxiety Effects 0.000 abstract description 4
- 208000026278 immune system disease Diseases 0.000 abstract description 4
- 208000030159 metabolic disease Diseases 0.000 abstract description 4
- 208000020016 psychiatric disease Diseases 0.000 abstract description 4
- 208000020925 Bipolar disease Diseases 0.000 abstract description 3
- 208000030979 Language Development disease Diseases 0.000 abstract description 3
- 208000036626 Mental retardation Diseases 0.000 abstract description 3
- 208000012902 Nervous system disease Diseases 0.000 abstract description 3
- 206010015037 epilepsy Diseases 0.000 abstract description 3
- 201000000980 schizophrenia Diseases 0.000 abstract description 3
- 208000025966 Neurological disease Diseases 0.000 abstract description 2
- 208000035475 disorder Diseases 0.000 description 75
- 239000000523 sample Substances 0.000 description 61
- 210000004027 cell Anatomy 0.000 description 44
- 150000007523 nucleic acids Chemical class 0.000 description 39
- 108020004707 nucleic acids Proteins 0.000 description 33
- 102000039446 nucleic acids Human genes 0.000 description 33
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 28
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 28
- 102000004169 proteins and genes Human genes 0.000 description 20
- 235000018102 proteins Nutrition 0.000 description 18
- 239000013615 primer Substances 0.000 description 17
- 239000002987 primer (paints) Substances 0.000 description 17
- 239000013598 vector Substances 0.000 description 17
- 101150084750 1 gene Proteins 0.000 description 15
- OGNSCSPNOLGXSM-UHFFFAOYSA-N (+/-)-DABA Natural products NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 description 14
- 108020004414 DNA Proteins 0.000 description 14
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 14
- 238000004458 analytical method Methods 0.000 description 13
- 238000000338 in vitro Methods 0.000 description 11
- 239000003446 ligand Substances 0.000 description 11
- 239000002773 nucleotide Substances 0.000 description 11
- 125000003729 nucleotide group Chemical group 0.000 description 11
- 108091026890 Coding region Proteins 0.000 description 9
- 230000027455 binding Effects 0.000 description 9
- 230000001105 regulatory effect Effects 0.000 description 9
- 230000000295 complement effect Effects 0.000 description 8
- 238000012217 deletion Methods 0.000 description 8
- 230000037430 deletion Effects 0.000 description 8
- 230000002068 genetic effect Effects 0.000 description 8
- 208000011231 Crohn disease Diseases 0.000 description 7
- 241000700605 Viruses Species 0.000 description 7
- 239000003153 chemical reaction reagent Substances 0.000 description 7
- 201000010099 disease Diseases 0.000 description 7
- 101150000874 11 gene Proteins 0.000 description 6
- 108020004711 Nucleic Acid Probes Proteins 0.000 description 6
- 102000037054 SLC-Transporter Human genes 0.000 description 6
- 108091006207 SLC-Transporter Proteins 0.000 description 6
- 238000003556 assay Methods 0.000 description 6
- 230000006399 behavior Effects 0.000 description 6
- 230000000875 corresponding effect Effects 0.000 description 6
- 230000006870 function Effects 0.000 description 6
- 239000002853 nucleic acid probe Substances 0.000 description 6
- 230000003997 social interaction Effects 0.000 description 6
- 239000000758 substrate Substances 0.000 description 6
- 101000639970 Homo sapiens Sodium- and chloride-dependent GABA transporter 1 Proteins 0.000 description 5
- 108091028043 Nucleic acid sequence Proteins 0.000 description 5
- 235000001014 amino acid Nutrition 0.000 description 5
- 150000001413 amino acids Chemical class 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 230000001771 impaired effect Effects 0.000 description 5
- 238000003780 insertion Methods 0.000 description 5
- 230000037431 insertion Effects 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 238000003127 radioimmunoassay Methods 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 238000009007 Diagnostic Kit Methods 0.000 description 4
- 101000996111 Homo sapiens Neuroligin-4, X-linked Proteins 0.000 description 4
- 101001125026 Homo sapiens Nucleotide-binding oligomerization domain-containing protein 2 Proteins 0.000 description 4
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 4
- 102100034441 Neuroligin-4, X-linked Human genes 0.000 description 4
- 102100029441 Nucleotide-binding oligomerization domain-containing protein 2 Human genes 0.000 description 4
- 238000013459 approach Methods 0.000 description 4
- 230000003542 behavioural effect Effects 0.000 description 4
- 210000004556 brain Anatomy 0.000 description 4
- 230000001364 causal effect Effects 0.000 description 4
- 230000002939 deleterious effect Effects 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- 229930195712 glutamate Natural products 0.000 description 4
- 108020004999 messenger RNA Proteins 0.000 description 4
- 239000002858 neurotransmitter agent Substances 0.000 description 4
- 102000054765 polymorphisms of proteins Human genes 0.000 description 4
- 238000001228 spectrum Methods 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 3
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 description 3
- 206010009900 Colitis ulcerative Diseases 0.000 description 3
- 238000002965 ELISA Methods 0.000 description 3
- 102000008214 Glutamate decarboxylase Human genes 0.000 description 3
- 108091022930 Glutamate decarboxylase Proteins 0.000 description 3
- 101001094098 Homo sapiens Sodium- and chloride-dependent GABA transporter 3 Proteins 0.000 description 3
- 108091092195 Intron Proteins 0.000 description 3
- 102000006890 Methyl-CpG-Binding Protein 2 Human genes 0.000 description 3
- 108010072388 Methyl-CpG-Binding Protein 2 Proteins 0.000 description 3
- 108091092878 Microsatellite Proteins 0.000 description 3
- 102100033927 Sodium- and chloride-dependent GABA transporter 1 Human genes 0.000 description 3
- 201000006704 Ulcerative Colitis Diseases 0.000 description 3
- 239000000427 antigen Substances 0.000 description 3
- 108091007433 antigens Proteins 0.000 description 3
- 102000036639 antigens Human genes 0.000 description 3
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 238000004891 communication Methods 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- 230000006735 deficit Effects 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 238000001415 gene therapy Methods 0.000 description 3
- 238000003205 genotyping method Methods 0.000 description 3
- 210000004602 germ cell Anatomy 0.000 description 3
- 210000003917 human chromosome Anatomy 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 210000004962 mammalian cell Anatomy 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 239000013612 plasmid Substances 0.000 description 3
- 208000013406 repetitive behavior Diseases 0.000 description 3
- 230000003989 repetitive behavior Effects 0.000 description 3
- 208000011580 syndromic disease Diseases 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 238000013518 transcription Methods 0.000 description 3
- 230000035897 transcription Effects 0.000 description 3
- 230000032258 transport Effects 0.000 description 3
- KISWVXRQTGLFGD-UHFFFAOYSA-N 2-[[2-[[6-amino-2-[[2-[[2-[[5-amino-2-[[2-[[1-[2-[[6-amino-2-[(2,5-diamino-5-oxopentanoyl)amino]hexanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-5-(diaminomethylideneamino)p Chemical compound C1CCN(C(=O)C(CCCN=C(N)N)NC(=O)C(CCCCN)NC(=O)C(N)CCC(N)=O)C1C(=O)NC(CO)C(=O)NC(CCC(N)=O)C(=O)NC(CCCN=C(N)N)C(=O)NC(CO)C(=O)NC(CCCCN)C(=O)NC(C(=O)NC(CC(C)C)C(O)=O)CC1=CC=C(O)C=C1 KISWVXRQTGLFGD-UHFFFAOYSA-N 0.000 description 2
- 206010067484 Adverse reaction Diseases 0.000 description 2
- 208000002267 Anti-neutrophil cytoplasmic antibody-associated vasculitis Diseases 0.000 description 2
- 208000023275 Autoimmune disease Diseases 0.000 description 2
- 108010078791 Carrier Proteins Proteins 0.000 description 2
- 108020004635 Complementary DNA Proteins 0.000 description 2
- 241000702421 Dependoparvovirus Species 0.000 description 2
- 230000009508 GABAergic inhibition Effects 0.000 description 2
- 101000603172 Homo sapiens Neuroligin-3 Proteins 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 208000026350 Inborn Genetic disease Diseases 0.000 description 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 2
- 108700018351 Major Histocompatibility Complex Proteins 0.000 description 2
- 102000047918 Myelin Basic Human genes 0.000 description 2
- 101710107068 Myelin basic protein Proteins 0.000 description 2
- 102100038940 Neuroligin-3 Human genes 0.000 description 2
- 238000000636 Northern blotting Methods 0.000 description 2
- 108091034117 Oligonucleotide Proteins 0.000 description 2
- 102100035254 Sodium- and chloride-dependent GABA transporter 3 Human genes 0.000 description 2
- 108700029631 X-Linked Genes Proteins 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- 230000021736 acetylation Effects 0.000 description 2
- 238000006640 acetylation reaction Methods 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000006838 adverse reaction Effects 0.000 description 2
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 2
- 201000007197 atypical autism Diseases 0.000 description 2
- 230000005784 autoimmunity Effects 0.000 description 2
- 230000005540 biological transmission Effects 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 210000005013 brain tissue Anatomy 0.000 description 2
- 238000010804 cDNA synthesis Methods 0.000 description 2
- 238000012412 chemical coupling Methods 0.000 description 2
- 238000007385 chemical modification Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000002759 chromosomal effect Effects 0.000 description 2
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 230000001276 controlling effect Effects 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000003623 enhancer Substances 0.000 description 2
- 238000007824 enzymatic assay Methods 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 238000002509 fluorescent in situ hybridization Methods 0.000 description 2
- 231100000221 frame shift mutation induction Toxicity 0.000 description 2
- 230000037433 frameshift Effects 0.000 description 2
- 208000016361 genetic disease Diseases 0.000 description 2
- -1 genomic DNA (gDNA) Chemical class 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 230000013595 glycosylation Effects 0.000 description 2
- 238000006206 glycosylation reaction Methods 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000006801 homologous recombination Effects 0.000 description 2
- 238000002744 homologous recombination Methods 0.000 description 2
- 230000003528 hypoglutamatergic effect Effects 0.000 description 2
- 230000010354 integration Effects 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 230000008140 language development Effects 0.000 description 2
- 238000007834 ligase chain reaction Methods 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 230000000869 mutational effect Effects 0.000 description 2
- 230000009871 nonspecific binding Effects 0.000 description 2
- 238000003499 nucleic acid array Methods 0.000 description 2
- 238000004806 packaging method and process Methods 0.000 description 2
- 238000003752 polymerase chain reaction Methods 0.000 description 2
- 108091033319 polynucleotide Proteins 0.000 description 2
- 102000040430 polynucleotide Human genes 0.000 description 2
- 239000002157 polynucleotide Substances 0.000 description 2
- 210000000063 presynaptic terminal Anatomy 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 230000008707 rearrangement Effects 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 230000003252 repetitive effect Effects 0.000 description 2
- 238000007423 screening assay Methods 0.000 description 2
- 238000005204 segregation Methods 0.000 description 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 108091078039 sodium:neurotransmitter symporter (SNF) family Proteins 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 230000009897 systematic effect Effects 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 238000001890 transfection Methods 0.000 description 2
- 238000013519 translation Methods 0.000 description 2
- 241000701161 unidentified adenovirus Species 0.000 description 2
- 241001430294 unidentified retrovirus Species 0.000 description 2
- 239000013603 viral vector Substances 0.000 description 2
- 230000001755 vocal effect Effects 0.000 description 2
- 239000003643 water by type Substances 0.000 description 2
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 208000009575 Angelman syndrome Diseases 0.000 description 1
- 108020005544 Antisense RNA Proteins 0.000 description 1
- 206010003591 Ataxia Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 206010006482 Bronchospasm Diseases 0.000 description 1
- 206010008805 Chromosomal abnormalities Diseases 0.000 description 1
- 208000031404 Chromosome Aberrations Diseases 0.000 description 1
- 208000011359 Chromosome disease Diseases 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 208000028698 Cognitive impairment Diseases 0.000 description 1
- 206010010947 Coordination abnormal Diseases 0.000 description 1
- 206010067477 Cytogenetic abnormality Diseases 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 238000000018 DNA microarray Methods 0.000 description 1
- 206010011971 Decreased interest Diseases 0.000 description 1
- 208000012239 Developmental disease Diseases 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 108700024394 Exon Proteins 0.000 description 1
- 208000001914 Fragile X syndrome Diseases 0.000 description 1
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 1
- 102000018899 Glutamate Receptors Human genes 0.000 description 1
- 108010027915 Glutamate Receptors Proteins 0.000 description 1
- 108091027305 Heteroduplex Proteins 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- 206010022714 Intestinal ulcer Diseases 0.000 description 1
- 241000235649 Kluyveromyces Species 0.000 description 1
- 108010006444 Leucine-Rich Repeat Proteins Proteins 0.000 description 1
- 101150083522 MECP2 gene Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 108091061960 Naked DNA Proteins 0.000 description 1
- 208000009905 Neurofibromatoses Diseases 0.000 description 1
- 102000008763 Neurofilament Proteins Human genes 0.000 description 1
- 108010088373 Neurofilament Proteins Proteins 0.000 description 1
- 108700002045 Nod2 Signaling Adaptor Proteins 0.000 description 1
- 102000050697 Nod2 Signaling Adaptor Human genes 0.000 description 1
- 108091092724 Noncoding DNA Proteins 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 201000011252 Phenylketonuria Diseases 0.000 description 1
- 101000955367 Pseudomonas putida Transcriptional regulatory protein XylR Proteins 0.000 description 1
- 206010037180 Psychiatric symptoms Diseases 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 206010061481 Renal injury Diseases 0.000 description 1
- 108091081062 Repeated sequence (DNA) Proteins 0.000 description 1
- 208000006289 Rett Syndrome Diseases 0.000 description 1
- 102000006382 Ribonucleases Human genes 0.000 description 1
- 108010083644 Ribonucleases Proteins 0.000 description 1
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 208000033340 Sex-chromosome anomaly Diseases 0.000 description 1
- 101710104417 Sodium- and chloride-dependent GABA transporter 3 Proteins 0.000 description 1
- 238000002105 Southern blotting Methods 0.000 description 1
- 208000026911 Tuberous sclerosis complex Diseases 0.000 description 1
- 208000024780 Urticaria Diseases 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 210000001789 adipocyte Anatomy 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 238000007844 allele-specific PCR Methods 0.000 description 1
- 208000036878 aneuploidy Diseases 0.000 description 1
- 231100001075 aneuploidy Toxicity 0.000 description 1
- 239000000164 antipsychotic agent Substances 0.000 description 1
- 208000024823 antisocial personality disease Diseases 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 239000012472 biological sample Substances 0.000 description 1
- 239000000090 biomarker Substances 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 230000005821 brain abnormality Effects 0.000 description 1
- 230000007885 bronchoconstriction Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 210000001638 cerebellum Anatomy 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
- 208000024971 chromosomal disease Diseases 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 229940121657 clinical drug Drugs 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 239000013599 cloning vector Substances 0.000 description 1
- 229960003920 cocaine Drugs 0.000 description 1
- 208000010877 cognitive disease Diseases 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 208000013407 communication difficulty Diseases 0.000 description 1
- 208000017856 coordination symptom Diseases 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000003936 denaturing gel electrophoresis Methods 0.000 description 1
- 230000009547 development abnormality Effects 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 238000002224 dissection Methods 0.000 description 1
- 239000003210 dopamine receptor blocking agent Substances 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 229940000406 drug candidate Drugs 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000007877 drug screening Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 210000002308 embryonic cell Anatomy 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 230000001037 epileptic effect Effects 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 238000002825 functional assay Methods 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 108091008053 gene clusters Proteins 0.000 description 1
- 102000054767 gene variant Human genes 0.000 description 1
- 230000004077 genetic alteration Effects 0.000 description 1
- 231100000118 genetic alteration Toxicity 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 230000004034 genetic regulation Effects 0.000 description 1
- 230000007614 genetic variation Effects 0.000 description 1
- 208000018231 gonosome anomaly Diseases 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 235000015220 hamburgers Nutrition 0.000 description 1
- 230000002489 hematologic effect Effects 0.000 description 1
- 102000047066 human SLC6A1 Human genes 0.000 description 1
- 210000004408 hybridoma Anatomy 0.000 description 1
- 230000036543 hypotension Effects 0.000 description 1
- 230000008105 immune reaction Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000002998 immunogenetic effect Effects 0.000 description 1
- 208000035231 inattentive type attention deficit hyperactivity disease Diseases 0.000 description 1
- 208000016290 incoordination Diseases 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000009830 intercalation Methods 0.000 description 1
- 210000004901 leucine-rich repeat Anatomy 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 238000004020 luminiscence type Methods 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 201000004931 neurofibromatosis Diseases 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 230000003557 neuropsychological effect Effects 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 239000000123 paper Substances 0.000 description 1
- 230000001936 parietal effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000008447 perception Effects 0.000 description 1
- 230000009984 peri-natal effect Effects 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 230000002974 pharmacogenomic effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000003169 placental effect Effects 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 239000013600 plasmid vector Substances 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 230000003234 polygenic effect Effects 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 238000003793 prenatal diagnosis Methods 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 210000001236 prokaryotic cell Anatomy 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 238000009163 protein therapy Methods 0.000 description 1
- 238000003906 pulsed field gel electrophoresis Methods 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 238000009256 replacement therapy Methods 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 210000002427 ring chromosome Anatomy 0.000 description 1
- 238000011808 rodent model Methods 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 239000012896 selective serotonin reuptake inhibitor Substances 0.000 description 1
- 229940124834 selective serotonin reuptake inhibitor Drugs 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000009151 sensory gating Effects 0.000 description 1
- 229940076279 serotonin Drugs 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 239000000021 stimulant Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000002636 symptomatic treatment Methods 0.000 description 1
- 230000007428 synaptic transmission, GABAergic Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 101150065190 term gene Proteins 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- 238000003146 transient transfection Methods 0.000 description 1
- 230000005945 translocation Effects 0.000 description 1
- 208000009999 tuberous sclerosis Diseases 0.000 description 1
- 241000701447 unidentified baculovirus Species 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 210000003501 vero cell Anatomy 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 210000005253 yeast cell Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Analytical Chemistry (AREA)
- Wood Science & Technology (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Psychology (AREA)
- Pathology (AREA)
- Pain & Pain Management (AREA)
- Biochemistry (AREA)
- Psychiatry (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US65637405P | 2005-02-28 | 2005-02-28 | |
| US60/656,374 | 2005-02-28 | ||
| PCT/IB2006/001100 WO2006090288A2 (en) | 2005-02-28 | 2006-02-27 | Human autism susceptibility genes encoding a neurotransmitter transporter and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2599327A1 true CA2599327A1 (en) | 2006-08-31 |
Family
ID=36607270
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002599327A Abandoned CA2599327A1 (en) | 2005-02-28 | 2006-02-27 | Human autism susceptibility genes encoding a neurotransmitter transporter and uses thereof |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20080213765A1 (https=) |
| EP (1) | EP1859060A2 (https=) |
| JP (1) | JP2008532499A (https=) |
| AU (1) | AU2006217543A1 (https=) |
| CA (1) | CA2599327A1 (https=) |
| IL (1) | IL184843A0 (https=) |
| WO (1) | WO2006090288A2 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101935673B (zh) * | 2009-07-03 | 2013-08-21 | 中国科学院上海生命科学研究院 | 用于抑制小鼠γ-氨基丁酸转运蛋白亚型1的siRNA |
| EP4055174A4 (en) | 2019-11-08 | 2024-01-03 | The Board Of Regents Of The University Of Texas System | TRANSGENIC CASSETTES, AAV VECTORS AND AAV VECTORS FOR EXPRESSING HUMAN CODON-OPTIMIZED SLCA1 |
| WO2021113773A2 (en) * | 2019-12-04 | 2021-06-10 | Pai Athma A | Identifying non-productive splice sites |
| IL301255A (en) * | 2020-10-09 | 2023-05-01 | UCB Biopharma SRL | Nucleic acid structures, viral vectors and viral particles |
| CA3207224A1 (en) * | 2021-02-02 | 2022-08-11 | Bryan GORE | Artificial expression constructs for modulating gene expression in gabaergic neurons and astrocytes |
| WO2023022269A1 (ko) * | 2021-08-20 | 2023-02-23 | 단국대학교 천안캠퍼스 산학협력단 | 주의력결핍 과잉행동장애의 예방 또는 치료용 약학적 조성물 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19911130A1 (de) * | 1999-03-12 | 2000-09-21 | Hager Joerg | Verfahren zur Identifikation chromosomaler Regionen und Gene |
| EP1554403A1 (en) * | 2002-10-10 | 2005-07-20 | K.U. Leuven Research and Development | Autism gene |
-
2006
- 2006-02-27 EP EP06744621A patent/EP1859060A2/en not_active Withdrawn
- 2006-02-27 JP JP2007557626A patent/JP2008532499A/ja not_active Withdrawn
- 2006-02-27 US US11/817,291 patent/US20080213765A1/en not_active Abandoned
- 2006-02-27 WO PCT/IB2006/001100 patent/WO2006090288A2/en not_active Ceased
- 2006-02-27 CA CA002599327A patent/CA2599327A1/en not_active Abandoned
- 2006-02-27 AU AU2006217543A patent/AU2006217543A1/en not_active Abandoned
-
2007
- 2007-07-26 IL IL184843A patent/IL184843A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP1859060A2 (en) | 2007-11-28 |
| AU2006217543A1 (en) | 2006-08-31 |
| US20080213765A1 (en) | 2008-09-04 |
| IL184843A0 (en) | 2007-12-03 |
| WO2006090288A2 (en) | 2006-08-31 |
| WO2006090288A3 (en) | 2006-11-02 |
| JP2008532499A (ja) | 2008-08-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20100240539A1 (en) | Human Autism Susceptibility Gene Encoding PRKCB1 and Uses Thereof | |
| EP1656458B1 (en) | Human autism susceptibility gene and uses thereof | |
| AU2005258838B2 (en) | Human autism predisposition gene encoding a transcription factor and uses thereof | |
| AU2006215385B2 (en) | Uses of human autism susceptibility gene encoding a kinase | |
| US20080213765A1 (en) | Human Autism Susceptibility Genes Encoding a Neurotransmitter Transporter and Uses Thereof | |
| AU2006225995B2 (en) | Human autism susceptibility gene encoding a transmembrane protein and uses thereof | |
| WO2006003526A2 (en) | Human autism susceptibility gene encoding otoa and uses thereof | |
| US20090208482A1 (en) | Human obesity susceptibility gene encoding a member of the neurexin family and uses thereof | |
| US20080286765A1 (en) | Human Obesity Susceptibility Gene Encoding a Taste Receptor and Uses Thereof | |
| AU2005254806A1 (en) | Human obesity susceptibility gene encoding a potassium voltage-gated channel and uses thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Discontinued |